The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who plans to retire in June next year.

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and representative director, effective from June 2026. The decision was unanimously reached by Takeda's board of directors.

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as the drugmaker’s new chief executive officer.

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price over the last couple of years.

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S. business unit.